$100B in NIH-fund­ed re­search played an im­por­tant role in all 210 new drugs ap­proved over 7 years — study

The next time some­one chal­lenges the im­por­tance of NIH-fund­ed re­search in drug de­vel­op­ment, you might want to point them to a new study that high­lights the foun­da­tion­al role the In­sti­tutes plays in bio­phar­ma re­search.

The study — pub­lished in the Pro­ceed­ings of the Na­tion­al Acad­e­my of Sci­ences — con­cludes that every one of the 210 new mol­e­c­u­lar en­ti­ties ap­proved by the FDA be­tween 2010 and 2016 can source re­search back to NIH-fund­ed work. That is es­pe­cial­ly im­por­tant in fig­ur­ing the pub­lic con­text of first-in-class work, where ba­sic re­search played a sig­nif­i­cant role in the sci­en­tif­ic un­der­stand­ing of the tar­gets in­volved.

From the study by a team of re­searchers at Bent­ley Uni­ver­si­ty:

These da­ta demon­strate that a siz­able pub­lic-sec­tor in­vest­ment oc­curs be­fore the ap­proval of first-in-class NMEs, par­tic­u­lar­ly those dis­cov­ered us­ing tar­get­ed dis­cov­ery meth­ods (in­clud­ing re­com­bi­nant bi­o­log­i­cals). The scale of this in­vest­ment can be es­ti­mat­ed from the costs as­so­ci­at­ed with first-in-class NMEs ap­proved in 2010–2016 and their mol­e­c­u­lar tar­gets. These da­ta sug­gest that the pub­lic-sec­tor in­vest­ment in re­search un­der­ly­ing each first-in-class drug is as high as $839 mil­lion, with 89% of this cost as­so­ci­at­ed with tar­get re­search and 11% of the cost as­so­ci­at­ed with the first-in-class com­pound or fol­low-on com­pounds ap­proved from 2010–2016….

Over­all, this analy­sis sug­gests that as much as 20% of the NIH bud­get al­lo­ca­tion from 2000–2016 (more than $100 bil­lion) was as­so­ci­at­ed with pub­lished re­search that di­rect­ly or in­di­rect­ly con­tributed to NMEs ap­proved from 2010–2016.

The au­thors in par­tic­u­lar want­ed to ex­pand the scope of their re­search to make sure they were ac­count­ing for NIH-fund­ed stud­ies that were es­sen­tial to a drug tar­get, which doesn’t al­ways fac­tor in­to the patents used to pro­tect the com­mer­cial val­ue of each drug — a stan­dard that had been used in ear­li­er at­tempts to high­light the role of the NIH in drug de­vel­op­ment.

No one at the NIH is like­ly to get any kick­back from bio­phar­ma on this score. NIH fund­ing has been un­der the gun un­der Pres­i­dent Don­ald Trump, who’s been ready to sac­ri­fice re­search spend­ing in fa­vor of oth­er pri­or­i­ties. But the NIH bud­get has been saved by a bi­par­ti­san pha­lanx of elect­ed of­fi­cials in Con­gress who have ral­lied against the cuts. They’ll be back on the front­line of this de­bate now that Trump has sub­mit­ted a new bud­get this week that calls on law­mak­ers to flat­line spend­ing at the In­sti­tutes.

Those de­fend­ers just got some fresh am­mu­ni­tion for the fights to come.

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is officially giving up on its oral SERD.

The French drugmaker put out word Wednesday morning that it will discontinue the global development program of amcenestrant, the selective estrogen receptor degrader once billed as a top late-stage prospect. Having already failed a Phase II monotherapy test earlier this year, a combo with the drug also missed the bar in a second trial for breast cancer, triggering the decision to drop the whole program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Tom Barnes, Orna Therapeutics CEO

UP­DAT­ED: 'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Merck went in deep on its collaboration with Moderna on new mRNA programs, and dropped them all over time, including their RSV partnership. But after writing off what turned out as one of the most successful infectious disease players in the business, Merck is coming in this morning with a new preclinical alliance — this time embracing a biotech that hopes to eventually outdo the famously successful mRNA in a new run at vaccines and therapeutics.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Kate Haviland, Blueprint Medicines CEO

Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

Blueprint Medicines announced this morning that the second part of its study on Ayvakit in non-advanced systemic mastocytosis (SM) — a rare disease in which a type of white blood cells known as mast cells builds up — met all endpoints, but the biopharma left key questions unanswered.

In 212 patients, with 141 in the treatment arm and 71 in the control arm, patients who got Ayvakit saw an average 15.6-point decrease in their symptom scores compared to a 9.2-point decrease in the placebo arm at 24 weeks. In an extension study, those on Ayvakit saw their symptom scores drop by 20.2 points by week 48.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has landed a new first from UNICEF the first-ever contract for malaria vaccines, worth up to $170 million for 18 million vaccine doses distributed over the next three years.

The vaccine, known as Mosquirix or RTS,S, won WHO’s backing last October after a controversial start, but UNICEF said these doses will potentially save thousands of lives every year.

“We hope this is just the beginning,” Etleva Kadilli, director of UNICEF’s supply division, said. “Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”

Joe Jonas (Photo by Anthony Behar/Sipa USA)(Sipa via AP Images)

So­lo Jonas broth­er car­ries Merz's new tune in Botox ri­val cam­paign

As the lyrics of his band’s 2019 pop-rock single suggest, Joe Jonas is only human — and that means even he gets frown lines. The 33-year-old singer-songwriter is Merz’s newest celebrity brand partner for its Botox rival Xeomin, as medical aesthetics brands target a younger audience.

Merz kicked off its “Beauty on Your Terms” campaign on Tuesday, featuring the Jonas brother in a video ad for its double-filtered anti-wrinkle injection Xeomin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.

Marisol Peron, Genmab SVP of communications and corporate affairs

Gen­mab launch­es cor­po­rate cam­paign am­pli­fy­ing its ‘knock your socks off’ an­ti­bod­ies

Genmab often talks about its “knock-your-socks-off” antibodies — and now the term is getting its own logo and corporate campaign.

The teal and purple logo for the acronym KYSO — Genmab pronounces it “ky-so” — debuts on Wednesday and comes on the heels of Genmab’s newly announced 2030 vision. That aspiration aims to expand Genmab’s drug development beyond oncology to include other serious diseases, while also doubling down on its own drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.